Pharmaceutical Technology11 小时
Risk adjusted net present value: What is the current valuation of Prothena Corp’s Birtamimab?
Birtamimab is a monoclonal antibody commercialized by Prothena Corp, with a leading Phase III program in Primary Systemic Amyloidosis.
GDF-15 inhibitors show promise against hard-to-treat tumors in clinical trial
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...
Pharmaceutical Technology11 小时
Risk adjusted net present value: What is the current valuation of Xencor’s Plamotamab?
Plamotamab is a monoclonal antibody commercialized by Xencor, with a leading Phase I program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL).
Asia One2 小时
'It sneaked in quietly, causing anxiety and confusion': Man shares struggles with ...
Hazwady Nazran, now 38, was hospitalised with mysterious and terrifying symptoms such as violent episodes, paranoid delusions, confusion, memory loss and seizures. If his wife, Dr Miria Hastuti ...